Company Overview of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company h...
75 Park Plaza
Boston, MA 02116
Founded in 2001
Key Executives for Paratek Pharmaceuticals, Inc.
Chairman of the Board and Chief Executive Officer
Total Annual Compensation: $349.0K
President, Chief Medical Officer and Director
Total Annual Compensation: $360.0K
Chief Financial Officer
Total Annual Compensation: $300.0K
Chief Commercial Officer and Vice President
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2015.
Paratek Pharmaceuticals, Inc. Key Developments
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2016; Reports Results of Phase 1b Study of Omadacycline in Patients with Urinary Tract Infections
Nov 2 16
Paratek Pharmaceuticals, Inc. reported earnings results for the third quarter ended September 30, 2016. The company reported a net loss of $23.6 million, or $1.04 per share, compared to a net loss of $23.4 million, or $1.33 per share, for the same period in 2015.
The company also reported the completion and top-line results of a Phase 1b study of omadacycline in patients with urinary tract infections, as well as the completion of several important clinical and manufacturing requirements for its planned NDA submission. Phase 1b UTI Pharmacokinetic Results In this clinical study, patients with uncomplicated UTI received either IV-to-oral or oral-only regimens of omadacycline over a period of five days. Results showed that omadacycline achieved high steady state concentrations in urine for all treatment regimens, demonstrating proof-of-principle for the use of omadacycline in UTI. Clinical & Manufacturing NDA Registration Requirements The company completed two required Phase 1 pharmacokinetic studies to support the planned regulatory filings for omadacycline. The first of the two Phase 1 studies assessed the concentration of omadacycline in the lungs via bronchoalveolar lavage (BAL). This study, conducted in healthy volunteer subjects, demonstrated that omadacycline is able to penetrate into the lungs and epithelial lining fluid, at concentrations higher than plasma. The second Phase 1 study evaluated exposure levels of omadacycline in patients with end-stage renal disease. This study found that in these patients, omadacycline had similar pharmacokinetic exposure profiles to healthy subjects, suggesting that omadacycline can be used in subjects with renal impairment without the need for dose adjustments. All recently completed phase 1 studies demonstrate a safety and tolerability profile consistent with prior oral and IV phase 1 studies of omadacycline. The company has also completed production of all oral and IV registration batches of omadacycline required for planned regulatory submissions. The registration batches were produced at commercial scale.
Paratek Pharmaceuticals, Inc. - Special Call
Oct 26 16
To discuss progress of the clinical development program for omadacycline
Paratek Pharmaceuticals, Inc. to Report Q3, 2016 Results on Nov 02, 2016
Oct 24 16
Paratek Pharmaceuticals, Inc. announced that they will report Q3, 2016 results at 5:26 PM, GMT Standard Time on Nov 02, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|